Evaluation of the Cepheid Xpert MTB/RIF assay

References

• ATS/CDC/IDSA. Diagnostic standards and classification of tuberculosis in adults and children. Am J Respir Crit Care Med 2000;161(4):1376-95
   PubMedGoogle Scholar
• World Health Organization. The global plan to stop TB 2011-2015: transforming the fight towards elimination of tuberculosis. WHO/HTM/STB/2010.2 World Health Organization, Geneva; 2010. Available from: www.stoptb.org/global/plan/
   Google Scholar
• Gomez-Pastrana D. Diagnosis of pulmonary tuberculosis in children. J Infect Dis Therap 2013;1:17-24
   Google Scholar
• Steingart KR, Schiller I, Horne DJ, et al. Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst Rev 2014;1:CD009593
   PubMed Web of Science ®Google Scholar
• Kik SV, Denkinger CM, Chedore P, Pai M. Replacing smear microscopy for the diagnosis of tuberculosis: what is the market potential? Eur Respir J 2014;43(6):1793-6
   PubMedGoogle Scholar
• Global Laboratory Initiative. A roadmap for ensuring quality tuberculosis laboratory services within national laboratory strategic plans. World Health Organization, Geneva; 2010. Available from: www.stoptb.org/wg/gli/assets/documents/GLI_Roadmap_First_Issue_2010110.pdf
   Google Scholar
• World Health Organization. Framework for implementing TB diagnostics; 2011. Available from: www.who.int/tb/laboratory/whopolicyframework_rev_june2011.pdf
   Google Scholar
• CDC. National plan for reliable tuberculosis laboratory services using a systems approach: recommendations from CDC and the Association of Public Health Laboratories Task Force on Tuberculosis Laboratory Services. MMWR Morb Mortal Wkly Rep 2005;54(No. RR-6):1-12
   PubMedGoogle Scholar
• Drobniewski FA, Hoffner S, Rusch-Gerdes S, WHO European Laboratory Strengthening Task Force. Recommended standards for modern tuberculosis laboratory services in Europe. Eur Respir J 2006;28(5):903-9
   PubMed Web of Science ®Google Scholar
• Canadian Thoracic Society. Canadian Tuberculosis Standards, 7th Edition. Canadian Respir J 2013.20(Suppl A). Available on-line only from www.respiratoryguidelines.ca/tb-standards-2013
   Google Scholar
• World Health Organization. Global tuberculosis report 2013. WHO/HTM/TB/2013.11 World Health Organization, Geneva; 2013. Available from: http://apps.who.int/iris/bitstream/10665/91355/1/9789241564656_eng.pdf
   Google Scholar
• World Health Organization. Policy guidance on drug-susceptibility testing (DST) of second-line antituberculosis drugs. WHO/HTM/TB/2008.392 World Health Organization, Geneva; 2008. Available from: http://whqlibdoc.who.int/hq/2008/WHO_HTM_TB_2008.392_eng.pdf
   Google Scholar
• Wells WA, Boehme CC, Cobelens FG, et al. Alignment of new tuberculosis drug regimens and drug susceptibility testing: a framework for action. Lancet Infect Dis 2013;13(5):449-58
   PubMedGoogle Scholar
• Dinnes J, Deeks J, Kunst H, et al. A systematic review of rapid diagnostic tests for the detection of tuberculosis infection. Health Technol Assess 2007;11:1-196
   PubMed Web of Science ®Google Scholar
• Flores LL, Pai M, Colford JMJr, Riley LW. In-house nucleic acid amplification tests for the detection of Mycobacterium tuberculosis in sputum specimens: meta-analysis and meta-regression. BMC Microbiol 2005;5:55-10.1186/1471-2180-5-55
   PubMed Web of Science ®Google Scholar
• World Health Organization. Molecular line probe assays for rapid screening of patients at risk of multidrug-resistant tuberculosis (MDR TB) Policy Statement. World Health Organization, Geneva; 2008. Available from: http://who.int/tb/features_archive/policy_statement.pdf
   Google Scholar
• Kurbatova EV, Cavanaugh JS, Shah NS, et al. Rifampicin-resistant Mycobacterium tuberculosis: susceptibility to isoniazid and other anti-tuberculosis drugs. Int J Tuberc Lung Dis 2012;16(3):355-7
   PubMed Web of Science ®Google Scholar
• Smith SE, Kurbatova EV, Cavanaugh JS, Cegielski JP. Global isoniazid resistance patterns in rifampin-resistant and rifampin-susceptible tuberculosis. Int J Tuberc Lung Dis 2012;16(2):203-5
   PubMed Web of Science ®Google Scholar
• Foundation for Innovative New Diagnostics. The EXPAND-TB Project. Available from: www.finddiagnostics.org/programs/scaling_up/unitaid_expand_tb/
   Google Scholar
• Helb D, Jones M, Story E, et al. Rapid detection of Mycobacterium tuberculosis and rifampin resistance by use of on-demand, near patient technology. J Clin Microbiol 2010;48(1):229-37
   PubMed Web of Science ®Google Scholar
• Stop TB partnership global laboratory initiative. Resources for WHO policy recommendations and supporting documents. Available from: www.stoptb.org/wg/gli/documents.asp?xpand=1
   Google Scholar
• Boehme C, Nicol MP, Nabeta P, et al. Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. Lancet 2011;377(9776):1495-505
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration, Medical Devices Advisory Committee. Discussion and recommendations regarding the classification of NAAT-based rapid M. tuberculosis diagnostics and the classification of interferon Gamma release assays; 2011. Available from: www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/MedicalDevices/MedicalDevicesAdvisoryCommittee/MicrobiologyDevicesPanel/UCM260828.pdf
   Google Scholar
• Food and Drug Administration. 501(k) decision summary for de novo request for evaluation of automatic class III designation for the Xpert® MTB/RIF Assay for use with the GeneXpert® Instrument Systems, including the GeneXpert® Diagnostic (Dx) Systems and the GeneXpert® Infinity Systems (2013). Available from: http://www.accessdata.fda.gov/cdrh_docs/reviews/K131706.pdf
   Google Scholar
• Xpert MTB/RIF assay. package insert Sunnyvale; CA: Cepheid: 2013
   Google Scholar
• World Health Organization. Handbook for guideline development. World Health Organization, Geneva; 2012. Available from: http://apps.who.int/iris/bitstream/10665/75146/1/9789241548441_eng.pdf
   Google Scholar
• Schünemann J, Oxman AD, Brozek J, et al. Grading quality of evidence and strength of recommendations for diagnostic tests and strategies. BMJ 2008;336:1106-10
   PubMed Web of Science ®Google Scholar
• Weyer K, Mirzayev F, Migliori GB, et al. Rapid molecular TB diagnosis: evidence, policy making and global implementation of Xpert MTB/RIF. Eur Respir J 2013;42(1):252-71
   PubMed Web of Science ®Google Scholar
• World Health Organization. Xpert MTB/RIF: expert Group Meeting Report. World Health Organization, Geneva; 2010. Available from: www.who.int/tb/laboratory/en/EGM_report
   Google Scholar
• World Health organization. Strategic and Technical Advisory Group for Tuberculosis (STAG-TB) –. Report of the 10th meeting. WHO/HTM/TB/2010.18 World Health Organization, Geneva; 2010. Available from: www.who.int/entity/tb/advisory_bodies/STAG_report2013.pdf
   Google Scholar
• World Health Organization. Automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF system. Policy statement. WHO/HTM/TB/2011.4 World Health Organization, Geneva; 2011. Available from: http://whqlibdoc.who.int/publications/2011/9789241501545_eng.pdf
   Google Scholar
• World Health Organization. WHO monitoring of Xpert MTB/RIF roll-out. Available from: www.who.int/tb/laboratory/mtbrifrollout/en/
   Google Scholar
• Denkinger CM, Schumacher SG, Boehme CC, et al. Xpert MTB/RIF assay for the diagnosis of extrapulmonary tuberculosis: a systematic review and meta-analysis. Eur Respir J 2014; Epub ahead of print; 10.1183/09031936.00007814
   Google Scholar
• World Health Organization. Automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF system for the diagnosis of pulmonary and extrapulmonary TB in adults and children: policy update. WHO/HTM/TB/2013.14 World Health Organization, Geneva; 2013. Available from: http://apps.who.int/iris/bitstream/10665/112472/1/9789241506335_eng.pdf?ua=1
   Google Scholar
• World Health Organization. Using the Xpert MTB/RIF assay to detect pulmonary and extrapulmonary tuberculosis and rifampicin resistance in adults and children. Expert Group Meeting Report. WHO/HTM/TB/2013.14 World Health Organization, Geneva: 2013. Available from: www.who.int/tb/laboratory/expert_group_report.pdf?ua=1
   Google Scholar
• Association of Public Health Laboratories. Laboratory considerations for use of Cepheid Xpert® MTB/RIF Assay (2013). Available from: www.aphl.org/AboutAPHL/publications/Documents/ID_2013Nov_Cepheid-Xpert-Fact-Sheet.pdf
   Google Scholar
• Centers for Disease Control and Prevention (CDC). Availability of an assay for detecting Mycobacterium tuberculosis, Including rifampin-resistant strains, and considerations for its use - United States, 2013. MMWR Morb Mortal Wkly Rep 2013;62(41):821-4
   PubMedGoogle Scholar
• Centers for Disease Control and Prevention (CDC). Updated guidelines for the use of nucleic acid amplification tests in the diagnosis of tuberculosis. MMWR Morb Mortal Wkly Rep 2009;58:7-10
   PubMedGoogle Scholar
• Centers for Disease Control and Prevention (CDC). Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care settings, 2005. MMWR Morb Mortal Wkly Rep 2005;54(No. RR-17):l
   Google Scholar
• Centers for Disease Control and Prevention (CDC). Reported tuberculosis in the United States, 2012. Department of Health and Human Services, CDC, Atlanta; 2013. Available from: www.cdc.gov/tb/statistics/reports/2012/pdf/report2012.pdf
   Google Scholar
• European Centre for Disease Prevention and Control. ERLN-TB expert opinion on the use of the rapid molecular assays for the diagnosis of tuberculosis and detection of drug-resistance. Stockholm: ECDC; 2013. ISBN 978-92-9193-483-6. doi:10.2900/8592. Catalogue number TQ-02-13-155-EN-C. Available from: www.ecdc.europa.eu/en/publications/Publications/ERLN-TB-use-rapid-molecular-assays-diagnosis-tuberculosis-detection-drug-resistance.pdf
   Google Scholar
• World Health Organization. Rapid implementation of the Xpert MTB/RIF diagnostic test. Technical and operational ‘How-to’ practical considerations. WHO/HTM/TB/2014.1 World Health Organization, Geneva; 2014. Available from: http://apps.who.int/iris/bitstream/10665/112469/1/9789241506700_eng.pdf?ua=1
   Google Scholar
• World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis – 2011 update. WHO/HTM/TB/2011.6 World Health Organization, Geneva; 2011. Available from: http://whqlibdoc.who.int/publications/2011/9789241501583_eng.pdf
   Google Scholar
• World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis: emergency update 2008. WHO/HTM/TB/2008.402 World Health Organization, Geneva; 2008. Available from: http://whqlibdoc.who.int/publications/2008/9789241547581_eng.pdf
   Google Scholar
• World Health Organization. Anti-tuberculosis drug resistance in the world: fourth global report. WHO/HTM/TB/2008.394 World Health Organization, Geneva; 2008. Available from: www.who.int/tb/publications/2008/drs_report4_26feb08.pdf
   Google Scholar
• Denkinger CM, Pai M, Dowdy DW. Do we need to detect isoniazid resistance in addition to rifampicin resistance in diagnostic tests for tuberculosis? PLoS One 2014;9(1):e84197
   Google Scholar
• Marlowe EM, Novak-Weekley SM, Cumpio J, et al. Evaluation of the Cepheid Xpert MTB/RIF assay for direct detection of Mycobacterium tuberculosis complex in respiratory specimens. J Clin Microbiol 2011;49(4):1621-3
   PubMedGoogle Scholar
• Bunsow E, Ruiz-Serrano MJ, López Roa P, et al. Evaluation of GeneXpert MTB/RIF for the detection of Mycobacterium tuberculosis and resistance to rifampin in clinical specimens. J Infect 2014;68(4):338-43
   PubMedGoogle Scholar
• Moure R, Muñoz L, Torres M, et al. Rapid detection of Mycobacterium tuberculosis complex and rifampin resistance in smear-negative clinical samples by use of an integrated real-time PCR method. J Clin Microbiol 2011;49(3):1137-9
   PubMed Web of Science ®Google Scholar
• Sohn H, Aero AD, Menzies D, et al. Xpert MTB/RIF testing in a low tuberculosis incidence, high-resource setting: limitations in accuracy and clinical impact. Clin Infect Dis 2014;58(7):970-6
   PubMed Web of Science ®Google Scholar
• Cepheid. Available from: www.cepheidcares.com/tb/cepheid-warranty.html
   Google Scholar
• Foundation for Innovative New Diagnostics. Available from: www.finddiagnostics.org/about/what_we_do/successes/find-negotiated-prices/xpert_mtb_rif.html
   Google Scholar
• Cepheid. Available from: www.cepheidcares.com/tb/cepheid-vision.html
   Google Scholar
• Millman AJ, Dowdy DW, Miller CR, et al. Rapid molecular testing for TB to guide respiratory isolation in the U.S.: A cost-benefit analysis. PLoS One 2013;8(11):e79669
   Google Scholar
• Vassall A, van Kampen S, Sohn H, et al. Rapid diagnosis of tuberculosis with the Xpert MTB/RIF assay in high burden countries: a cost-effectiveness analysis. PLoS Med 2011;8(11):e1001120
   PubMed Web of Science ®Google Scholar
• TB diagnostics market analysis consortium. Market assessment of tuberculosis diagnostics in Brazil in 2012. PloS One 2014;9(8):e104105
   Google Scholar
• Lippincott CK, Miller MB, Popowitch EB, et al. Xpert MTB/RIF assay shortens airborne isolation for hospitalized patients with presumptive tuberculosis in the United States. Clin Infect Dis 2014;59(2):186-92
   PubMed Web of Science ®Google Scholar
• Muñoz L, Moure R, Porta N, et al. GeneXpert® for smear-negative pulmonary tuberculosis: does it play a role in low-burden countries? Diagn Microbiol Infect Dis 2013;75(3):325-6
   PubMedGoogle Scholar
• Choi HW, Miele K, Dowdy D, Shah M. Cost-effectiveness of Xpert® MTB/RIF for diagnosing pulmonary tuberculosis in the United States. Int J Tuberc Lung Dis 2013;17(10):1328-35
   PubMedGoogle Scholar
• Andrews JR, Lawn SD, Rusu C, et al. The cost-effectiveness of routine tuberculosis screening with Xpert MTB/RIF prior to initiation of antiretroviral therapy: a model-based analysis. AIDS 2012;26(8):987-95
   PubMed Web of Science ®Google Scholar
• Abimbola TO, Marston BJ, Date AA, et al. Cost-effectiveness of tuberculosis diagnostic strategies to reduce early mortality among persons with advanced HIV infection initiating antiretroviral therapy. AIDS 2012;60(1):e1-7
   Google Scholar
• Pantoja A, Fitzpatrick C, Vassall A, et al. Xpert MTB/RIF for diagnosis of tuberculosis and drug-resistant tuberculosis: a cost and affordability analysis. Eur Respir J 2013;42(3):708-20
   PubMed Web of Science ®Google Scholar
• Schnippel K, Meyer-Rath G, Long L, et al. Diagnosing Xpert MTB/RIF negative TB: impact and cost of alternative algorithms for South Africa. S Afr Med J 2013;103(2):101-6
   PubMedGoogle Scholar
• Meyer-Rath G, Schnippel K, Long L, et al. The impact and cost of scaling up GeneXpert MTB/RIF in South Africa. PLoS One 2012;7(5):e36966
   PubMed Web of Science ®Google Scholar
• da Silva Antunes R, Pinto M, Trajman A. Patient costs for the diagnosis of tuberculosis in Brazil: comparison of Xpert MTB/RIF and smear microscopy. Int J Tuberc Lung Dis 2014;18:547-51
   PubMedGoogle Scholar
• Hanrahan CF, Selibas K, Deery CB, et al. Time to treatment and patient outcomes among TB suspects screened by a single point-of-care Xpert MTB/RIF at a primary care clinic in Johannesburg, South Africa. PLoS One 2013;8(6):e65421
   Google Scholar
• Lawn SD, Brooks SV, Kranzer K, et al. Screening for HIV-associated tuberculosis and rifampicin resistance before antiretroviral therapy using the Xpert MTB/RIF assay: a prospective study. PLoS Med 2011;8(7):e1001067
   PubMed Web of Science ®Google Scholar
• Lawn SD, Kerkhoff AD, Vogt M, Wood R. HIV-associated tuberculosis: relationship between disease severity and the sensitivity of new sputum-based and urine-based diagnostic assays. BMC Med 2013;11:231
   PubMedGoogle Scholar
• Theron G, Zijenah L, Chanda D, et al. Feasibility, accuracy, and clinical effect of point-of-care Xpert MTB/RIF testing for tuberculosis in primary-care settings in Africa: a multicentre, randomised, controlled trial. Lancet 2014;383(9915):424-35
   PubMed Web of Science ®Google Scholar
• Lawn SD, Kerkhoff AD, Vogt M, et al. Characteristics and early outcomes of patients with Xpert MTB/RIF-negative pulmonary tuberculosis diagnosed during screening before antiretroviral therapy. Clin Infect Dis 2012;54(8):1071-9
   PubMedGoogle Scholar
• Theron G, Peter J, Meldau R, et al. Accuracy and impact of Xpert MTB/RIF for the diagnosis of smear-negative or sputum-scarce tuberculosis using bronchoalveolar lavage fluid. Thorax 2013;68(11):1043-51
   PubMed Web of Science ®Google Scholar
• Theron G, Peter J, Dowdy D, et al. Do high rates of empirical treatment undermine the potential effect of new diagnostic tests for tuberculosis in high-burden settings? Lancet Infect Dis 2014;14(6):527-32
   PubMedGoogle Scholar
• Creswell J, Codlin AJ, Andre E, et al. Results from early programmatic implementation of Xpert MTB/RIF testing in nine countries. BMC Infect Dis 2014;14:2
   PubMedGoogle Scholar
• Lorent N, Choun K, Thai S, et al. Community-based active tuberculosis case finding in poor urban settlements of Phnom Penh, Cambodia: a feasible and effective strategy. PLoS ONE 2014;9(3):e92754
   Google Scholar
• Naidoo P, du Toit E, Dunbar R, et al. A comparison of multidrug-resistant tuberculosis treatment commencement times in MDRTBPlus line probe assay and Xpert MTB/RIF-based algorithms in a routine operational setting in Cape Town. PLoS One 2014;9:e103328
   Google Scholar
• Scott LE, Gous N, Cunningham BE, et al. Dried culture spots for Xpert MTB/RIF external quality assessment: results of a phase 1 pilot study in South Africa. J Clin Microbiol 2011;49:4356-60
   PubMedGoogle Scholar
• Gous N, Cunningham B, Kana B, et al. Performance monitoring of Mycobacterium tuberculosis dried culture spots for use with the GeneXpert system within a national program in South Africa. J Clin Microbiol 2013;51:4018-21
   PubMedGoogle Scholar
• Scott L, Albert H, Gilpin C, et al. Multicenter feasibility study to assess external quality assessment panels for Xpert MTB/RIF assay in South Africa. J Clin Microbiol 2014;52:2493-9
   PubMedGoogle Scholar
• Kwak N, Choi SM, Lee J, et al. Diagnostic accuracy and turnaround time of the Xpert MTB/RIF assay in routine clinical practice. PLoS One 2013;8(10):e77456
   Google Scholar
• Boyles TH, Hughes J, Cox V, et al. False-positive Xpert MTB/RIF assays in previously treated patients: need for caution in interpreting results. Int J Tuberc Lung Dis 2014;18(7):876-8
   PubMedGoogle Scholar
• Van Deun A, Maug AKJ, Bola V, et al. Rifampicin drug resistance tests for tuberculosis: challenging the gold standard. J Clin Microbiol 2013;51(8):2633-40
   PubMed Web of Science ®Google Scholar
• Rigouts L, Gumusboga M, Bram de Rijka W, et al. Rifampin resistance missed in automated liquid culture system for Mycobacterium tuberculosis isolates with specific rpoB mutations. J Clin Microbiol 2013;51(8):2641-5
   PubMed Web of Science ®Google Scholar
• Ocheretina O, Escuyer VE, Mabou M, et al. Correlation between genotypic and phenotypic testing for resistance to rifampin in Mycobacterium tuberculosis clinical isolates in Haiti: investigation of cases with discrepant susceptibility results. PLoS One 2014;9(3):e90569
   Google Scholar
• Williamson DA, Basu I, Bower J, et al. An evaluation of the Xpert MTB/RIF assay and detection of false-positive rifampicin resistance in Mycobacterium tuberculosis. Diagn Microbiol Infect Dis 2012;74:207-9
   PubMedGoogle Scholar
• Alonso M, Palacios JJ, Herranz M, et al. Isolation of Mycobacterium tuberculosis strains with a silent mutation in rpoB leading to potential misassignment of resistance category. J Clin Microbiol 2011;49(7):2688-90
   PubMed Web of Science ®Google Scholar
• Moure R, Martin R, Alcaide F. Silent mutation in rpoB detected from clinical samples with rifampin-susceptible Mycobacterium tuberculosis. J Clin Microbiol 2011;49(10):3722
   PubMedGoogle Scholar
• Van Rie A, Mellet K, John MA, et al. False-positive rifampicin resistance on Xpert® MTB/RIF: case report and clinical implications. Int J Tuberc Lung Dis 2012;16(2):206-8
   PubMed Web of Science ®Google Scholar
• Foundation for Innovative New Diagnostics. Performance of Xpert MTB/RIF Version G4 assay. Available from: www.stoptb.org/wg/gli/assets/documents/map/findg4cartridge.pdf
   Google Scholar
• Deggim V, Somoskovi A, Voit A, et al. Integrating the Xpert MTB/RIF assay into a diagnostic workflow for rapid detection of Mycobacterium tuberculosis in a low-prevalence area. J Clin Microbiol 2013;51(7):2396-9
   PubMed Web of Science ®Google Scholar
• Somoskovi A, Deggim V, Ciardo D, Bloemberg GV. Diagnostic implications of inconsistent results obtained with the Xpert MTB/Rif assay in detection of Mycobacterium tuberculosis isolates with an rpoB mutation associated with low-level rifampin resistance. J Clin Microbiol 2013;51(9):3127-9
   PubMed Web of Science ®Google Scholar
• Zetola NM, Shin SS, Tumedi KA, et al. Mixed Mycobacterium tuberculosis complex infections and false-negative results for rifampin resistance by GeneXpert MTB/RIF are associated with poor clinical outcomes. J Clin Microbiol 2014;52(7):2422-9
   PubMedGoogle Scholar
• Comas I, Borrell S, Roetzer A, et al. Whole-genome sequencing of rifampicin-resistant Mycobacterium tuberculosis strains identifies compensatory mutations in RNA polymerase genes. Nat Genet 2011;44(1):106-10
   PubMed Web of Science ®Google Scholar
• Casali N, Nikolayevsky V, Balabanova Y, et al. Evolution and transmission of drug-resistant tuberculosis in a Russian population. Nat Genet 2014;46:279-86
   PubMed Web of Science ®Google Scholar
• Merker M, Kohl TA, Roetzer A, et al. Whole genome sequencing reveals complex evolution patterns of multidrug-resistant Mycobacterium tuberculosis Beijing strains in patients. PLoS One 2013;8(12):e82551
   PubMed Web of Science ®Google Scholar
• Farhat MR, Shapiro BJ, Kieser KJ, et al. Genomic analysis identifies targets of convergent positive selection in drug-resistant Mycobacterium tuberculosis. Nat Genet 2013;45:1183-9
   PubMed Web of Science ®Google Scholar
• Springer B, Lucke K, Calligaris-Maibach R, et al. Quantitative drug susceptibility testing of Mycobacterium tuberculosis by use of MGIT 960 and EpiCenter instrumentation. J Clin Microbiol 2009;47:1773-80
   PubMedGoogle Scholar
• Centers for Disease Control and Prevention (CDC). Laboratory user guide for U.S. Public Health Laboratories: molecular detection of drug resistance (MDDR) in Mycobacterium tuberculosis complex by DNA sequencing. CDC. Atlanta; 2012. Available from: www.cdc.gov/tb/topic/laboratory/MDDRUsersGuide.pdf
   Google Scholar
• UNITAID. Tuberculosis diagnostic technology and market landscape: 3rd Edition. World Health Organization, Geneva; 2014. Available from: http://unitaid.org/images/marketdynamics/publications/UNITAID_TB_Diagnostics_Landscape_3rd-edition.pdf
   Google Scholar
• Dunne WMJr, Westblade LF, Ford B. Next-generation and whole-genome sequencing in the diagnostic clinical microbiology laboratory. Eur J Clin Microbiol Infect Dis 2012;31(8):1719-26
   PubMed Web of Science ®Google Scholar